These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1822 related articles for article (PubMed ID: 32296030)

  • 1. Targeting cancer stem cell pathways for cancer therapy.
    Yang L; Shi P; Zhao G; Xu J; Peng W; Zhang J; Zhang G; Wang X; Dong Z; Chen F; Cui H
    Signal Transduct Target Ther; 2020 Feb; 5(1):8. PubMed ID: 32296030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer stem cells (CSCs) in cancer progression and therapy.
    Najafi M; Farhood B; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells.
    Silva VR; Santos LS; Dias RB; Quadros CA; Bezerra DP
    Cancer Commun (Lond); 2021 Dec; 41(12):1275-1313. PubMed ID: 34791817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncofetal proteins and cancer stem cells.
    Yan Q; Fang X; Li C; Lan P; Guan X
    Essays Biochem; 2022 Sep; 66(4):423-433. PubMed ID: 35670043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncogenic potential of NANOG: An important cancer induction mediator.
    Najafzadeh B; Asadzadeh Z; Motafakker Azad R; Mokhtarzadeh A; Baghbanzadeh A; Alemohammad H; Abdoli Shadbad M; Vasefifar P; Najafi S; Baradaran B
    J Cell Physiol; 2021 Apr; 236(4):2443-2458. PubMed ID: 32960465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling pathways and microRNAs, the orchestrators of NANOG activity during cancer induction.
    Alemohammad H; Asadzadeh Z; Motafakker Azad R; Hemmat N; Najafzadeh B; Vasefifar P; Najafi S; Baradaran B
    Life Sci; 2020 Nov; 260():118337. PubMed ID: 32841661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
    Wang D; Fu L; Sun H; Guo L; DuBois RN
    Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells.
    Mimeault M; Batra SK
    J Cell Mol Med; 2013 Jan; 17(1):30-54. PubMed ID: 23301832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4, KLF4, Sox2, Nanog).
    Lee S; Wottrich S; Bonavida B
    Tumour Biol; 2017 Apr; 39(4):1010428317692253. PubMed ID: 28378634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.
    Clara JA; Monge C; Yang Y; Takebe N
    Nat Rev Clin Oncol; 2020 Apr; 17(4):204-232. PubMed ID: 31792354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic approaches targeting cancer stem cells.
    Pan Y; Ma S; Cao K; Zhou S; Zhao A; Li M; Qian F; Zhu C
    J Cancer Res Ther; 2018; 14(7):1469-1475. PubMed ID: 30589025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Stem Cells and their Management in Cancer Therapy.
    Shenouda S; Kulkarni K; Abuetabh Y; Sergi C
    Recent Pat Anticancer Drug Discov; 2020; 15(3):212-227. PubMed ID: 32660407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer stem cells: advances in knowledge and implications for cancer therapy.
    Chu X; Tian W; Ning J; Xiao G; Zhou Y; Wang Z; Zhai Z; Tanzhu G; Yang J; Zhou R
    Signal Transduct Target Ther; 2024 Jul; 9(1):170. PubMed ID: 38965243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel reporter construct for screening small molecule inhibitors that specifically target self-renewing cancer cells.
    Shanmugam G; Mohan A; Kumari K; Louis JM; Soumya Krishnan U; Balagopal PG; George NA; Sebastian P; Maliekal TT
    Exp Cell Res; 2019 Oct; 383(2):111551. PubMed ID: 31401066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to Cell Death and Its Modulation in Cancer Stem Cells.
    Safa AR
    Crit Rev Oncog; 2016; 21(3-4):203-219. PubMed ID: 27915972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem cells and novel targets for antitumor strategies.
    Prud'homme GJ
    Curr Pharm Des; 2012; 18(19):2838-49. PubMed ID: 22390767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Cancer Stem Cells Pathways for the Effective Treatment of Cancer.
    Dwivedi AR; Thakur A; Kumar V; Skvortsova I; Kumar V
    Curr Drug Targets; 2020; 21(3):258-278. PubMed ID: 31433755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
    Bourguignon LY; Wong G; Earle C; Chen L
    J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug discovery approaches to target Wnt signaling in cancer stem cells.
    Curtin JC; Lorenzi MV
    Oncotarget; 2010 Nov; 1(7):563-577. PubMed ID: 21317452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.